Pelzer et al reported the CONKO score for predicting the risk of venous thromboembolism in a patient with cancer. This is a modification of the Khorana score. The authors are from Charite Universitatsmedizin Berlin (Medizinische Klinik mit Schwerpunkt Hamatologie, Onkologie und Tumorimmunologie) with patients enrolled in the CONKO-004 trial.
Patient selection: oncology
Parameters:
(1) tumor risk for venous thromboembolism
(2) prechemotherapy anemia (hemoglobin or use of erythropoietin stimulating agent)
(3) prechemotherapy white blood cell count
(4) prechemotherapy platelet count
(5) WHO performance status
Parameter
Finding
Points
tumor risk
very high (gastric, pancreas)
2
high (lung, ovarian, bladder)
1
other
0
prechemotherapy anemia
hemoglobin < 10 g/dL
1
receiving erythropoietin stimulating agent
1
other
0
prechemotherapy WBC
<= 11 * 10^9/L
0
> 11 * 10^9/L
1
prechemotherapy platelet count
< 350 * 10^9/L
0
>= 350 * 10^9/L
1
WHO performance status
0 or 1
0
2 to 4
1
total score =
= SUM(points for all 5 parameters)
Interpretation:
• minimum score: 0
• maximum score: 6
• A score >= 3 is associated with high risk of venous thromboembolism.
To read more or access our algorithms and calculators, please log in or register.
